The relationship between mycobacterium tuberculosis mgit time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 2, 2015, Pages 448-455

  Bowness, Ruth ^a   Boeree, Martin J ^b   Aarnoutse, Rob ^b   Dawson, Rodney ^c   Diacon, Andreas ^d   Mangu, Chacha ^e   Heinrich, Norbert ^f,g   Ntinginya, Nyanda E ^e   Kohlenberg, Anke ^e,f   Mtafya, Bariki ^e   Phillips, Patrick P J ^h   Rachow, Andrea ^f,g   Plemper van balen, Georgette ^b   Gillespie, Stephen H ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

^e NIMRMbeya Medical Research Centre   (Tanzania)

^f UNIVERSITY OF MUNICH   (Germany)

^g German Centre for Infection Research (DZIF)   (Germany)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

M. tuberculosis; TB; TTP

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADD ON THERAPY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL; BACTERIAL LOAD; BACTERIUM CULTURE; COLONY FORMING UNIT; CULTURE MEDIUM; DATA ANALYSIS SOFTWARE; DRUG DOSE INCREASE; DRUG EFFICACY; GROWTH CHAMBER; HUMAN; MATHEMATICAL MODEL; MONOTHERAPY; MYCOBACTERIAL GROWTH INDICATOR TUBE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PHENOTYPIC VARIATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPUTUM; TIME; TIME TO POSITIVITY; TREND STUDY; TUBE; TUBERCULOSIS; ADOLESCENT; ADULT; AGED; BIOLOGICAL MODEL; DRUG EFFECTS; FEMALE; INFORMATION PROCESSING; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; DATASETS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; SPUTUM; TUBERCULOSIS; YOUNG ADULT;

EID: 84922424155     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku415     Document Type: Article

References (23)

1. Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis 2010; 90: 162-7.
2. Chao MC, Rubin EJ. Letting sleeping dogs lie: does dormancy play a role in tuberculosis? Annu Rev Microbiol 2010; 64: 293-311.
3. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-9.
4. Shleeva MO, Kudykina YK, Vostroknutova GN et al. Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. Tuberculosis (Edinb) 2011; 91: 146-54.
5. Hu Y, Coates ARM, Mitchison DA. Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008; 12: 69-73.
6. Jindani A, Aber VR, Edwards EA et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-49.
7. Grosset J, Almeida D, Converse PJ et al. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci USA 2012; 109: 15001-5.
8. Garton NJ, Christensen H, Minnikin DE et al. Intracellular lipophilic inclusions of mycobacteria in vitro and in sputum. Microbiology 2002; 148: 2951-8.
9. Shleeva MO, Bagramyan K, Telkov MV et al. Formation and resuscitation of 'non-culturable' cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. Microbiology 2002; 148: 1581-91.
10. Mukamolova GV, Kaprelyants AS, Young DI et al. A bacterial cytokine. Proc Natl Acad Sci USA 1998; 95: 8916-21.
11. Deb C, Lee C-M, Dubey VS et al. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS One 2009; 4: e6077.
12. Loebel RO, Shorr E, Richardson HB. The influence of adverse conditions upon the respiratory metabolism and growth of human tubercle bacilli. J Bacteriol 1933; 26: 167-200.
13. Wayne LG. Growth of Mycobacterium tuberculosis from resected specimens under various atmospheric conditions.AmRev Tuberc 1954; 70: 910-1.
14. Davies AP, Dhillon AP, Young M et al. Resuscitation-promoting factors are expressed in Mycobacterium tuberculosis-infected human tissue. Tuberculosis 2008; 88: 462-8.
15. Mukamolova GV, Turapov O, Malkin J et al. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 2010; 181: 174-80.
16. Diacon AH, Maritz JS, Venter A et al. Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect 2012; 18: 711-7.
17. Gillespie SH. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother 2005; 56: 1169-71.
18. Perrin FMR,Woodward N, Phillips PPJ et al. Radiological cavitation, sputum mycobacterial load and treatment response in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010; 14: 1596-602.
19. Thorburn CE, Molesworth SJ, Sutherland R et al. Postantibiotic and post-β-lactamase inhibitor effects of amoxicillin plus clavulanate. Antimicrob Agents Chemother 1996; 40: 2796-801.
20. Gumbo T, Louie A, Deziel MR et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51: 3781-8.
21. de Steenwinkel JEM, Aarnoutse RE, de Knegt GJ et al. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment, using a murine model. Am J Respir Crit Care Med 2013; 187: 1127-34.
22. Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167: 1348-54.
23. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 2001; 23: 100-14.